These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 8056697)

  • 1. Efficacy of ciprofloxacin in treatment and prophylaxis of experimental Staphylococcus aureus endocarditis caused by a cloxacillin-tolerant strain and its non-tolerant variant.
    Voorn GP; Thompson J; Goessens WH; Schmal-Bauer WC; Broeders PH; Michel MF
    J Antimicrob Chemother; 1994 Apr; 33(4):785-94. PubMed ID: 8056697
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Role of tolerance in treatment and prophylaxis of experimental Staphylococcus aureus endocarditis with vancomycin, teicoplanin, and daptomycin.
    Voorn GP; Kuyvenhoven J; Goessens WH; Schmal-Bauer WC; Broeders PH; Thompson J; Michel MF
    Antimicrob Agents Chemother; 1994 Mar; 38(3):487-93. PubMed ID: 8203842
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Role of tolerance in cloxacillin prophylaxis of experimental Staphylococcus aureus endocarditis.
    Voorn GP; Thompson J; Goessens WH; Schmall-Bauer W; Broeders PH; Michel MF
    J Infect Dis; 1992 Jul; 166(1):169-73. PubMed ID: 1607692
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Paradoxical dose effect of continuously administered cloxacillin in treatment of tolerant Staphylococcus aureus endocarditis in rats.
    Voorn GP; Thompson J; Goessens WH; Schmal-Bauer WC; Broeders PH; Michel MF
    J Antimicrob Chemother; 1994 Mar; 33(3):585-93. PubMed ID: 8040122
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Role of tolerance in cloxacillin treatment of experimental Staphylococcus aureus endocarditis.
    Voorn GP; Thompson J; Goessens WH; Schmal-Bauer W; Broeders PH; Michel MF
    J Infect Dis; 1991 Mar; 163(3):640-3. PubMed ID: 1995736
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacies of moxifloxacin, ciprofloxacin, and vancomycin against experimental endocarditis due to methicillin-resistant Staphylococcus aureus expressing various degrees of ciprofloxacin resistance.
    Entenza JM; Que YA; Vouillamoz J; Glauser MP; Moreillon P
    Antimicrob Agents Chemother; 2001 Nov; 45(11):3076-83. PubMed ID: 11600359
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative activity of cloxacillin and vancomycin against methicillin-susceptible Staphylococcus aureus experimental endocarditis.
    Fernández Guerrero ML; de Górgolas M
    J Antimicrob Chemother; 2006 Nov; 58(5):1066-9. PubMed ID: 16931540
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment of Staphylococcus aureus endocarditis in rats with coumermycin A1 and ciprofloxacin, alone or in combination.
    Perronne CM; Malinverni R; Glauser MP
    Antimicrob Agents Chemother; 1987 Apr; 31(4):539-43. PubMed ID: 3606060
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative efficacy of daptomycin, vancomycin, and cloxacillin for the treatment of Staphylococcus aureus endocarditis in rats and role of test conditions in this determination.
    Cantoni L; Glauser MP; Bille J
    Antimicrob Agents Chemother; 1990 Dec; 34(12):2348-53. PubMed ID: 1965105
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy of fleroxacin in experimental methicillin-resistant Staphylococcus aureus endocarditis.
    Kaatz GW; Seo SM; Barriere SL; Albrecht LM; Rybak MJ
    Antimicrob Agents Chemother; 1989 Apr; 33(4):519-21. PubMed ID: 2499251
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of vancomycin minimal inhibitory concentration on the outcome of methicillin-susceptible Staphylococcus aureus endocarditis.
    Cervera C; Castañeda X; de la Maria CG; del Rio A; Moreno A; Soy D; Pericas JM; Falces C; Armero Y; Almela M; Ninot S; Pare JC; Mestres CA; Gatell JM; Marco F; Miro JM;
    Clin Infect Dis; 2014 Jun; 58(12):1668-75. PubMed ID: 24647021
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparative efficacy of amoxicillin-clavulanate, cloxacillin, and vancomycin against methicillin-sensitive and methicillin-resistant Staphylococcus aureus endocarditis in rats.
    Cantoni L; Wenger A; Glauser MP; Bille J
    J Infect Dis; 1989 May; 159(5):989-93. PubMed ID: 2708846
    [No Abstract]   [Full Text] [Related]  

  • 13. The emergence of resistance to ciprofloxacin during treatment of experimental Staphylococcus aureus endocarditis.
    Kaatz GW; Barriere SL; Schaberg DR; Fekety R
    J Antimicrob Chemother; 1987 Nov; 20(5):753-8. PubMed ID: 3429376
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of ciprofloxacin for experimental endocarditis caused by methicillin-susceptible or -resistant strains of Staphylococcus aureus.
    Carpenter TC; Hackbarth CJ; Chambers HF; Sande MA
    Antimicrob Agents Chemother; 1986 Sep; 30(3):382-4. PubMed ID: 3640590
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Levofloxacin versus ciprofloxacin, flucloxacillin, or vancomycin for treatment of experimental endocarditis due to methicillin-susceptible or -resistant Staphylococcus aureus.
    Entenza JM; Vouillamoz J; Glauser MP; Moreillon P
    Antimicrob Agents Chemother; 1997 Aug; 41(8):1662-7. PubMed ID: 9257737
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Teicoplanin versus cloxacillin, cloxacillin-gentamycin and vancomycin in the treatment of experimental endocarditis caused by methicillin-sensitive Staphylococcus aureus].
    Apellaniz G; Valdés M; Pérez R; Martín-Luengo F; García A; Soria F; Gómez J
    Enferm Infecc Microbiol Clin; 1991 Apr; 9(4):208-10. PubMed ID: 1830757
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of the effectiveness of various antibiotics in the treatment of methicillin-susceptible Staphylococcus aureus experimental infective endocarditis.
    Apellaniz G; Valdés M; Perez R; Martin F; Soria F; Garcia A; Gòmez J; Vicente T
    J Chemother; 1991 Apr; 3(2):91-7. PubMed ID: 1875239
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ciprofloxacin versus vancomycin in the therapy of experimental methicillin-resistant Staphylococcus aureus endocarditis.
    Kaatz GW; Barriere SL; Schaberg DR; Fekety R
    Antimicrob Agents Chemother; 1987 Apr; 31(4):527-30. PubMed ID: 3649202
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CI-960, a new fluoroquinolone, for therapy of experimental ciprofloxacin-susceptible and -resistant Staphylococcus aureus endocarditis.
    Kaatz GW; Seo SM; Lamp KC; Bailey EM; Rybak MJ
    Antimicrob Agents Chemother; 1992 Jun; 36(6):1192-7. PubMed ID: 1329613
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ciprofloxacin therapy of experimental endocarditis caused by methicillin-susceptible or methicillin-resistant Staphylococcus aureus.
    Fernandez-Guerrero M; Rouse M; Henry N; Wilson W
    Antimicrob Agents Chemother; 1988 May; 32(5):747-51. PubMed ID: 3164989
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.